About one quarter of patients with overactive bladder were taking their initial oral regimen at nearly 3 years, yet most reported symptom improvement.
|Articles|August 1, 2013
Peter Goldbach, MD, Says Providers Can Engage Patients in Making Informed Decisions
Peter Goldbach, MD, Chief Medical Officer, Health Dialog, says providers must engage their patients by communicating information about their health in efficient ways.
Advertisement
Peter Goldbach, MD, Chief Medical Officer, Health Dialog, says providers must engage their patients by communicating information about their health in efficient ways. Dr Goldbach says the most critical interaction in healthcare is that between a doctor and their patient. The more informed a patient is, the more successful that interaction will be.
Advertisement
Related to this article
Alternating platelet-rich plasma and intralesional corticosteroids was well tolerated in a pediatric Asian patient with severe alopecia areata.
Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Mirabegron was not tied to higher obesity-related neoplasm risk vs antimuscarinics in overactive bladder, but all-cause mortality was higher.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
A poster at the ASCO Quality Care Symposium describes how a value-based care partnership used prior authorization data and pharmacist workflows to move eligible patients off flat dosing of pembrolizumab.
Advertisement
Advertisement
Trending on AJMC
1
Retatrutide Tops Semaglutide on A1C, Weight in Head-to-Head Trial
2
At the Pharmacy, Affordability Connects Policy, Plans, and Patients
3
UAB Works to Deliver Cutting-Edge Cancer Therapies, Reach Every Patient
4
Olanzapine/Samidorphan Tied to Longer Persistence in Schizophrenia
5